Soleno Therapeutics (SLNO) Operating Expenses: 2013-2017
Historic Operating Expenses for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to $5.2 million.
- Soleno Therapeutics' Operating Expenses rose 183.62% to $5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was $12.2 million, marking a year-over-year increase of 18.21%. This contributed to the annual value of $187.7 million for FY2024, which is 353.49% up from last year.
- Per Soleno Therapeutics' latest filing, its Operating Expenses stood at $5.2 million for Q4 2017, which was up 97.61% from $2.6 million recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Operating Expenses ranged from a high of $5.2 million in Q4 2017 and a low of $559,783 during Q4 2013.
- For the 3-year period, Soleno Therapeutics' Operating Expenses averaged around $2.9 million, with its median value being $2.8 million (2017).
- As far as peak fluctuations go, Soleno Therapeutics' Operating Expenses surged by 255.26% in 2015, and later plummeted by 67.69% in 2017.
- Over the past 5 years, Soleno Therapeutics' Operating Expenses (Quarterly) stood at $559,783 in 2013, then surged by 229.72% to $1.8 million in 2014, then skyrocketed by 89.17% to $3.5 million in 2015, then slumped by 47.50% to $1.8 million in 2016, then skyrocketed by 183.62% to $5.2 million in 2017.
- Its Operating Expenses stands at $5.2 million for Q4 2017, versus $2.6 million for Q3 2017 and $3.0 million for Q2 2017.